The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Mutant p53 gain-of-function induces epithelial–mesenchymal transition through modulation of the miR-130b–ZEB1 axis
Open accessAbstract
The tumor suppressor gene p53 has been implicated in the regulation of epithelial-mesenchymal transition (EMT) and tumor metastasis by regulating microRNA (miRNA) expression. Here, we report that mutant p53 exerts oncogenic functions and promotes EMT in endometrial cancer (EC) by directly binding to the promoter of miR-130b (a negative regulator of ZEB1) and inhibiting its transcription. We transduced p53 mutants into p53-null EC cells, profiled the miRNA expression by miRNA microarray and identified miR-130b as a potential target of mutant p53. Ectopic expression of p53 mutants repressed the expression of miR-130b and triggered ZEB1-dependent EMT and cancer cell invasion. Loss of an endogenous p53 mutation increased the expression of miR-130b, which resulted in reduced ZEB1 expression and attenuation of the EMT phenotype. Furthermore, re-expression of miR-130b suppressed mutant p53-induced EMT and ZEB1 expression. Importantly, the expression of miR-130 was significantly reduced in EC tissues, and patients with higher expression levels of miR-130b survived longer. These data provide a novel understanding of the roles of p53 gain-of-function mutations in accelerating tumor progression and metastasis through modulation of the miR-130b-ZEB1 axis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
RETRACTED: Downregulation of miR‐122 in the rodent and human hepatocellular carcinomas
Kutay, H., Bai, S., Datta, J., Motiwala, T., Pogribny, I., Frankel, W., Jacob, S. T., & Ghoshal, K. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20982 · Cited by 608
RetractedTransactivation of the EGR1 Gene Contributes to Mutant p53 Gain of Function
Weisz, L., Zalcenstein, A., Stambolsky, P., Cohen, Y., Goldfinger, N., Oren, M., & Rotter, V. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1145 · Cited by 129
RetractedMicroRNA expression profiles classify human cancers
Lu, J., Getz, G., Miska, E. A., Alvarez-Saavedra, E., Lamb, J., Peck, D., Sweet-Cordero, A., Ebert, B. L., Mak, R. H., Ferrando, A. A., et al. (2005) · Nature · doi:10.1038/nature03702 · Cited by 9,539
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs
Wellner, U., Schubert, J., Burk, U. C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., Vannier, C., Darling, D., Hausen, A. Z., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1998 · Cited by 1,699
Korpal, M., Lee, E. S., Hu, G., & Kang, Y. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800074200 · Cited by 1,645
Epithelial-Mesenchymal Transitions
Kang, Y., & Massagué, J. (2004) · Cell · doi:10.1016/j.cell.2004.07.011 · Cited by 1,525
Transcriptional Activation of miR-34a Contributes to p53-Mediated Apoptosis
Raver-Shapira, N., Marciano, E., Meiri, E., Spector, Y., Rosenfeld, N., Moskovits, N., Bentwich, Z., & Oren, M. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.05.017 · Cited by 1,352
Rivlin, N., Brosh, R., Oren, M., & Rotter, V. (2011) · Genes & Cancer · doi:10.1177/1947601911408889 · Cited by 1,033
Mutant p53 Gain-of-Function in Cancer
Oren, M., & Rotter, V. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753
p53 regulates epithelial–mesenchymal transition and stem cell properties through modulating miRNAs
Chang, C.-J., Chao, C.-H., Xia, W., Yang, J.-Y., Xiong, Y., Li, C.-W., Yu, W.-H., Rehman, S. K., Hsu, J. L., Lee, H.-H., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2173 · Cited by 745
Modulation of Activity of the Promoter of the Human MDR 1 Gene by Ras and p53
Chin, K.-V., Ueda, K., Pastan, I., & Gottesman, M. M. (1992) · Science · doi:10.1126/science.1346476 · Cited by 726
Li, Y., VandenBoom, T. G., Kong, D., Wang, Z., Ali, S., Philip, P. A., & Sarkar, F. H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1298 · Cited by 663
p53 regulates epithelial–mesenchymal transition through microRNAs targeting ZEB1 and ZEB2
Kim, T., Veronese, A., Pichiorri, F., Lee, T. J., Jeon, Y.-J., Volinia, S., Pineau, P., Marchio, A., Palatini, J., Suh, S.-S., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110235 · Cited by 514
Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer
Zhang, L., Volinia, S., Bonome, T., Calin, G. A., Greshock, J., Yang, N., Liu, C.-G., Giannakakis, A., Alexiou, P., Hasegawa, K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801615105 · Cited by 511
p53-Responsive MicroRNAs 192 and 215 Are Capable of Inducing Cell Cycle Arrest
Braun, C. J., Zhang, X., Savelyeva, I., Wolff, S., Moll, U. M., Schepeler, T., Ørntoft, T. F., Andersen, C. L., & Dobbelstein, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1569 · Cited by 473
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs
Su, X., Chakravarti, D., Cho, M. S., Liu, L., Gi, Y. J., Lin, Y.-L., Leung, M. L., El-Naggar, A., Creighton, C. J., Suraokar, M. B., et al. (2010) · Nature · doi:10.1038/nature09459 · Cited by 419
Di Agostino, S., Strano, S., Emiliozzi, V., Zerbini, V., Mottolese, M., Sacchi, A., Blandino, G., & Piaggio, G. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.013 · Cited by 418
Hurst, D. R., Edmonds, M. D., Scott, G. K., Benz, C. C., Vaidya, K. S., & Welch, D. R. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3559 · Cited by 411
Ma, S., Tang, K. H., Chan, Y. P., Lee, T. K., Kwan, P. S., Castilho, A., Ng, I., Man, K., Wong, N., To, K.-F., et al. (2010) · Cell Stem Cell · doi:10.1016/j.stem.2010.11.010 · Cited by 383
Bandres, E., Bitarte, N., Arias, F., Agorreta, J., Fortes, P., Agirre, X., Zarate, R., Diaz-Gonzalez, J. A., Ramirez, N., Sola, J. J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1818 · Cited by 346
Cochrane, D. R., Spoelstra, N. S., Howe, E. N., Nordeen, S. K., & Richer, J. K. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1046 · Cited by 320
Prognostic Values of microRNAs in Colorectal Cancer.
Xi, Y., Formentini, A., Chien, M., Weir, D. B., Russo, J. J., Ju, J., Kornmann, M., & Ju, J. (2006) · PubMed Central · Cited by 267
Self-citationMicroRNA Signature Distinguishes the Degree of Aggressiveness of Papillary Thyroid Carcinoma
Yip, L., Kelly, L., Shuai, Y., Armstrong, M. J., Nikiforov, Y. E., Carty, S. E., & Nikiforova, M. N. (2011) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1733-0 · Cited by 242
Micro‐RNA signature of the epithelial–mesenchymal transition in endometrial carcinosarcoma
Castilla, M. Á., Moreno‐Bueno, G., Romero‐Pérez, L., De Vijver, K. V., Biscuola, M., López‐García, M. Á., Prat, J., Matías‐Guiu, X., Cano, A., Oliva, E., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2802 · Cited by 226
Forrest, A. R. R., Kanamori-Katayama, M., Tomaru, Y., Lassmann, T., Ninomiya, N., Takahashi, Y., de Hoon, M. J. L., Kubosaki, A., Kaiho, A., Suzuki, M., et al. (2010) · Leukemia · doi:10.1038/leu.2009.246 · Cited by 223
Dong, P., Kaneuchi, M., Watari, H., Hamada, J., Sudo, S., Ju, J., & Sakuragi, N. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-99 · Cited by 220
Self-citationXi, Y., Shalgi, R., Fodstad, O., Pilpel, Y., & Ju, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1853 · Cited by 212
Self-citationDirect p53 Transcriptional Repression: In Vivo Analysis of CCAAT-Containing G2/M Promoters
Imbriano, C., Gurtner, A., Cocchiarella, F., Di Agostino, S., Basile, V., Gostissa, M., Dobbelstein, M., Del Sal, G., Piaggio, G., & Mantovani, R. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.9.3737-3751.2005 · Cited by 207
Meng, Z., Fu, X., Chen, X., Zeng, S., Tian, Y., Jove, R., Xu, R., & Huang, W. (2010) · Hepatology · doi:10.1002/hep.23915 · Cited by 204
miR-143 Interferes with ERK5 Signaling, and Abrogates Prostate Cancer Progression in Mice
Clapé, C., Fritz, V., Henriquet, C., Apparailly, F., Fernandez, P. L., Iborra, F., Avancès, C., Villalba, M., Culine, S., & Fajas, L. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007542 · Cited by 198
Frazier, M. W., He, X., Wang, J., Gu, Z., Cleveland, J. L., & Zambetti, G. P. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.7.3735 · Cited by 194
Navon, R., Wang, H., Steinfeld, I., Tsalenko, A., Ben-Dor, A., & Yakhini, Z. (2009) · PLoS ONE · doi:10.1371/journal.pone.0008003 · Cited by 165
Kogan-Sakin, I., Tabach, Y., Buganim, Y., Molchadsky, A., Solomon, H., Madar, S., Kamer, I., Stambolsky, P., Shelly, A., Goldfinger, N., et al. (2010) · Cell Death and Differentiation · doi:10.1038/cdd.2010.94 · Cited by 161
Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression
Scian, M. J., Stagliano, K. E., Anderson, M. A. E., Hassan, S., Bowman, M., Miles, M. F., Deb, S. P., & Deb, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.22.10097-10110.2005 · Cited by 152
Song, B., Wang, Y., Kudo, K., Gavin, E. J., Xi, Y., & Ju, J. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1422 · Cited by 150
Self-citationZEB1 expression in type I vs type II endometrial cancers: a marker of aggressive disease
Singh, M., Spoelstra, N. S., Jean, A., Howe, E. N., Torkko, K. C., Clark, H. R., Darling, D. S., Shroyer, K. R., Horwitz, K. B., Broaddus, R. R., et al. (2008) · Modern Pathology · doi:10.1038/modpathol.2008.82 · Cited by 138
Zalcenstein, A., Stambolsky, P., Weisz, L., Müller, M., Wallach, D., Goncharov, T. M., Krammer, P. H., Rotter, V., & Oren, M. (2003) · Oncogene · doi:10.1038/sj.onc.1206724 · Cited by 123
Tumor-derived p53 mutants induce oncogenesis by transactivating growth-promoting genes
Scian, M. J., Stagliano, K. E., Deb, D., Ellis, M. A., Carchman, E. H., Das, A., Valerie, K. C., Deb, S. P., & Deb, S. (2004) · Oncogene · doi:10.1038/sj.onc.1207553 · Cited by 120
Yang, C., Cai, J., Wang, Q., Tang, H., Cao, J., Wu, L., & Wang, Z. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.10.013 · Cited by 119
Transcriptional activities of mutant p53: When mutations are more than a loss
Kim, E. L., & Deppert, W. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20271 · Cited by 102
Gualberto, A., & Baldwin, A. S. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.34.19680 · Cited by 101
Sun, Y., Cheung, J. M., Martel‐Pelletier, J., Pelletier, J. P., Wenger, L., Altman, R. D., Howell, D. S., & Cheung, H. S. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.11327 · Cited by 97
Mutant p53 Forms a Complex with Sp1 on HIV-LTR DNA
Chicas, A., Molina, P. E., & Bargonetti, J. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3965 · Cited by 69
Dong, P., Xu, Z., Jia, N., Li, D., & Feng, Y. (2009) · Molecular Cancer · doi:10.1186/1476-4598-8-103 · Cited by 68
Self-citationNovel DNA binding of p53 mutants and their role in transcriptional activation.
Zhang, W., Funk, W. D., Wright, W. E., Shay, J. W., & Deisseroth, A. (1993) · PubMed · Cited by 64
p53 DNA binding can be modulated by factors that alter the conformational equilibrium
McLure, K. G., & Lee, P. W. K. (1999) · The EMBO Journal · doi:10.1093/emboj/18.3.763 · Cited by 53
Repression of the MSP/MST-1 gene contributes to the antiapoptotic gain of function of mutant p53
Zalcenstein, A., Weisz, L., Stambolsky, P., Bar, J., Rotter, V., & Oren, M. (2005) · Oncogene · doi:10.1038/sj.onc.1209061 · Cited by 50
VEGF Expression and its Reguration by p53 Gene Transfection in Endometrial Carcinoma Cells
Fujisawa, T., Watanabe, J., Kamata, Y., Hamano, M., Hata, H., & Kuramoto, H. (2003) · Human Cell · doi:10.1111/j.1749-0774.2003.tb00128.x · Cited by 13
Cited by
Regulatory networks defining EMT during cancer initiation and progression
Craene, B. D., & Berx, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3447 · Cited by 2,487
Muller, P. A. J., & Vousden, K. H. (2013) · Nature Cell Biology · doi:10.1038/ncb2641 · Cited by 1,647
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities
Muller, P. A. J., & Vousden, K. H. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.021 · Cited by 1,545
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Epithelial Plasticity: A Common Theme in Embryonic and Cancer Cells
Nieto, M. A. (2013) · Science · doi:10.1126/science.1234850 · Cited by 967
Metadata
- Authors
- Dong, P., Karaayvaz, M., Jia, N., Kaneuchi, M., Hamada, J., Watari, H., Sudo, S., Ju, J., & Sakuragi, N.
- Venue
- Oncogene
- Published
- 2012-07-30
- Volume
- 32
- Issue
- 27
- Pages
- 3286-3295
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2080392221
- Cited by
- 307
- References
- 49
- FWCI
- 7.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.